Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

References

• Centers for Disease Control and PreventionRecommendations for identification and public health management of persons with chronic hepatitis B virus infectionMMWR Recomm Rep200857RR-8120
   Google Scholar
• MitchellAEColvinHMPalmer BeasleyRInstitute of Medicine recommendations for the prevention and control of hepatitis B and CHepatology20105172973320186842
   PubMed Web of Science ®Google Scholar
• LeeTAVeenstraDLIloejeUHSullivanSDCost of chronic hepatitis B infection in the United StatesJ Clin Gastroenterol20043810 Suppl 3S144S14715602162
   PubMed Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis B: update 2009Hepatology20095066166219714720
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis BJ Hepatol2012In press
   Google Scholar
• FontanaRJManagement of patients with decompensated HBV cirrhosisSemin Liver Dis2003238910012616454
   PubMed Web of Science ®Google Scholar
• LiawYFSungJJChowWCLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med20043511521153115470215
   PubMed Web of Science ®Google Scholar
• SchiffELaiCLHadziyannisSAdefovir dipivoxil for waitlisted and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term resultsLiver Transpl20071334936017326221
   PubMed Web of Science ®Google Scholar
• LiawYFRaptopoulou-GigiMCheinquerHEfficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensationHepatology2011549110021503940
   PubMed Web of Science ®Google Scholar
• Baraclude^® (entecavir) US prescribing informationBristol-Myers Squibb CompanyPrinceton, NJ 08543122010
   Google Scholar
• SpackmanDEVeenstraDLA cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis BPharmacoeconomics20082693794918850763
   PubMed Web of Science ®Google Scholar
• ArnoldEYuanYIloejeUCookGCost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis BAppl Health Econ Health Policy2008623124619382822
   PubMedGoogle Scholar
• ButiMBrosaMCasadoMARuedaMEstebanRModeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis BJ Hepatol20095164064619576651
   PubMed Web of Science ®Google Scholar
• KanwalFGralnekIMMartinPDulaiGSFaridMSpiegelBMTreatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysisAnn Intern Med200514282183115897532
   PubMed Web of Science ®Google Scholar
• KanwalFFaridMMartinPTreatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysisAm J Gastroenterol20061012076208916968510
   PubMed Web of Science ®Google Scholar
• VeenstraDLSullivanSDClarkeLCost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis BPharmacoeconomics20072596397717960954
   PubMed Web of Science ®Google Scholar
• YuanYIloejeUHHayJSaabSEvaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patientsJ Manag Care Pharm200814213318240879
   PubMed Web of Science ®Google Scholar
• SiegelJETorranceGWRussellLBLuceBRWeinsteinMCGoldMRGuidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicinePharmacoeconomics19971115916810172935
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network. [website on the Internet]Liver Kaplan-Meier percentage transplanted at specific time points for registrations listed: 1999–2004 Available from: http://optn.transplant.hrsa.govAccessed July 15, 2011
   Google Scholar
• HauboldtRHHansonSG2008US organ and tissue transplant cost estimates and discussionMilliman Research Report42008
   Google Scholar
• AltekruseSFMcGlynnKAReichmanMEHepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005J Clin Oncol2009271485149119224838
   PubMed Web of Science ®Google Scholar
• Red Book 2008Red Book for Windows Version 6112750Montvale, New JerseyThomson PDR2008
   Google Scholar
• TagTRubensteinEAMCP guide to pharmaceutical payment methods, 2009 updates (version 2.0)J Manag Care Pharm200915Suppl 6aS1S61
   Google Scholar
• The Pharmacy Benefit Management Institute. [website on the Internet]Prescription drug benefit cost and plan design report, 2008–2009 edition. Takeda Pharmaceuticals North America, Inc. November 2008The Pharmacy Benefit Management Institute2011 Available from: http://www.pbmi.com/2008_report/pdfs/Revised_Report_20112009.pdfAccessed July 27, 2011
   Google Scholar
• LangKDanchenkoNGondekKShahSThompsonDThe burden of illness associated with hepatocellular carcinoma in the United StatesJ Hepatol200950899918977551
   PubMed Web of Science ®Google Scholar
• Centres for Medicare and Medicaid Services. [website on the Internet]CMS Medicare and Medicaid Statistical Supplement 2010 Edition Available from: http://www.cms.gov/MedicareMedicaidStatSupp/09_2010.aspAccessed July 15, 2011
   Google Scholar
• GoodmanDCFisherESChangC-HQuality of end-of-life cancer care for Medicare beneficiaries: regional and hospital-specific analyses. A report of the Dartmouth Atlas ProjectLebanon, New HampshireDartmouth Institute for Health Policy and Clinical Practice2010
   Google Scholar
• NauglerWESonnenbergASurvival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinomaLiver Transpl2010161186119420879017
   PubMed Web of Science ®Google Scholar
• MazzaferroVRegaliaEDociRLiver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosisN Eng J Med1996334693699
   PubMed Web of Science ®Google Scholar
• BestJHVeenstraDLGeppertJTrends in expenditures for Medicare liver transplant recipientsLiver Transpl2001785886211679983
   PubMed Web of Science ®Google Scholar
• JingWMenaELiMTreatment patterns, healthcare use and costs associated with first-line treatment for chronic hepatitis B with entecavir versus tenofovirHepatology201154Suppl 1 Abstract 481
   Google Scholar
• LiawY-FSheenI-SLeeC-MTenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseHepatology201153627221254162
   PubMed Web of Science ®Google Scholar
• PostSESodhiNKPengCHWanKPollackHJA simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effectiveHealth Aff (Millwood)20113034034821289356
   PubMed Web of Science ®Google Scholar